How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its earnings results on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.08. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $22.71 million. Zogenix had a negative net margin of 278.38% and a negative trailing twelve-month return on equity of 91.20%. The business's revenue was up 690.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share.

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix Chief Executive Officer Stephen Farr, Ph.D. on Glassdoor.com . Stephen Farr, Ph.D. has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH) , Gilead Sciences (GILD) , Vanda Pharmaceuticals (VNDA) , AbbVie (ABBV) , QUALCOMM (QCOM) , Advanced Micro Devices (AMD) , Sorrento Therapeutics (SRNE) , Southwest Airlines (LUV) and Micron Technology (MU) .

NASDAQ:ZGNX

Zogenix (ZGNX) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free ZGNX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $26.68
▼
$26.68
50-Day Range: $26.10
▼
$26.68
52-Week Range: $11.03
▼
$26.90

Volume: 94 shs
Average Volume: 3.76 million shs
Market Capitalization: $1.50 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Zogenix alerts:

Ad DTI

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

About Zogenix Stock (NASDAQ:ZGNX)

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

ZGNX Stock News Headlines

March 23, 2024 | morningstar.com

Hwasung Industrial Co Ltd 002460

July 6, 2023 | fool.com

Alcon (NYSE: ALC)

April 18, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

May 21, 2023 | morningstar.com

Longeveron Inc Ordinary Shares - Class A

October 11, 2022 | businesswire.com

How Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats - Business Wire

September 30, 2022 | forbes.com

Biocryst Pharmaceuticals

September 26, 2022 | marketscreener.com

Nippon Shinyaku : Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome - Marketscreener.com

September 13, 2022 | marketscreener.com

PROMIS NEUROSCIENCES INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

April 18, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

September 10, 2022 | bizjournals.com

How Women Lead appoints three new executive board members - Bizwomen - The Business Journals

September 9, 2022 | bizjournals.com

East Bay Biotech Companies - San Francisco Business Times - The Business Journals

September 9, 2022 | prnewswire.com

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - PR Newswire

September 8, 2022 | streetinsider.com

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - StreetInsider.com

September 7, 2022 | finance.yahoo.com

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - Yahoo Finance

August 30, 2022 | bizjournals.com

With early-cancer detection technology, Delfi Diagnostics looks to beat out Guardant Health, Illumina's Grail and others - San Francisco Business Times - The Business Journals

August 29, 2022 | thestreet.com

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

August 23, 2022 | prnewswire.com

Delfi Diagnostics Adds Finance and Market Access Leadership as It Prepares for Commercial Launch - PR Newswire

August 16, 2022 | businesswire.com

Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - Business Wire

August 15, 2022 | streetinsider.com

Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - StreetInsider.com

August 9, 2022 | businesswire.com

Dravet Syndrome Treatment Market Report 2022-2029: Stiripentol and Cannabidiol to Contribute to Significant Growth of 11.7% - ResearchAndMarkets.com - Business Wire

August 3, 2022 | streetinsider.com

Tevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board - StreetInsider.com

August 2, 2022 | prnewswire.com

Geno Hires First Chief Legal Officer on Path to Accelerate the Transition to More Sustainable Materials - PR Newswire

July 28, 2022 | marketscreener.com

UCB : Strong first six months – UCB with continued delivery and strong resilience - Marketscreener.com

June 25, 2022 | gurufocus.com

Adamis Appoints Vickie Reed to Board of Directors - GuruFocus.com

June 24, 2022 | marketscreener.com

UCB : updates financial guidance for 2022 while maintaining 2025 financial guidance - Marketscreener.com

June 8, 2022 | businesswire.com

ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology - Business Wire

June 8, 2022 | seekingalpha.com

UCB's therapy gets FDA orphan drug status to treat seizures linked with rare epilepsy - Seeking Alpha

See More Headlines

Receive ZGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:ZGNX
CUSIP: 98978L10
CIK: 1375151
Web: www.zogenix.com
Phone: (510) 550-8300
Fax: 858-259-1166
Employees: 218
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-209,380,000.00
Net Margins: -278.38%
Pretax Margin: -278.26%
Return on Equity: -91.20%
Return on Assets: -43.60%

Debt

Debt-to-Equity Ratio: 0.88
Current Ratio: 3.63
Quick Ratio: 4.74

Sales & Book Value

Annual Sales: $81.69 million
Price / Sales: 18.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.64 per share
Price / Book: 4.02

Miscellaneous

Outstanding Shares: 56,227,000
Free Float: 53,922,000
Market Cap: $1.50 billion
Optionable: Optionable
Beta: 0.89

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Stephen James Farr
President, Chief Executive Officer & Director
Ashish M. Sagrolikar
Chief Operating Officer & Executive Vice President
Michael Patrick Smith
Chief Financial Officer, Treasurer & Executive VP
Bradley S. Galer
Chief Medical Officer & Executive Vice President
Steven A. Johnson
Vice President, Legal Council & Compliance Office

Key Competitors

View All Competitors

ZGNX Stock Analysis - Frequently Asked Questions

How were Zogenix's earnings last quarter?: Zogenix, Inc. (NASDAQ:ZGNX) released its earnings results on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.08. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $22.71 million. Zogenix had a negative net margin of 278.38% and a negative trailing twelve-month return on equity of 91.20%. The business's revenue was up 690.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share.
What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?: 7 employees have rated Zogenix Chief Executive Officer Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among the company's employees.
What other stocks do shareholders of Zogenix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

This page (NASDAQ:ZGNX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zogenix (ZGNX) Stock Price, News & Analysis

About Zogenix Stock (NASDAQ:ZGNX)

ZGNX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ZGNX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info